Kangstem Biotech is showing strong performance. The news that it will attend BIO USA held in San Diego, USA, from the 3rd to the 6th of next month and hold partnering meetings with more than 20 multinational pharmaceutical companies seems to be influencing its stock price.
As of 10:36 AM on the 30th, Kangstem Biotech was trading at 2,870 KRW, up 345 KRW (13.66%) compared to the previous trading day.
Kangstem Biotech stated, "Dermatology specialist pharmaceutical companies from Spain, major pharmaceutical companies from France, and global large pharmaceutical companies have requested discussions on the clinical trial procedures in the US and Europe following the domestic Phase 3 clinical trial of the atopic stem cell treatment 'Purestem-ADju.'"
Interest is also high in Purestem-OA Kitju, for which MRI-based radiological evaluation results for the low-dose group in Phase 1 clinical trials were secured last month. Meetings are being held with several major European pharmaceutical companies and domestic pharmaceutical companies focusing on structural improvement results such as pain relief, cartilage regeneration, and inflammation reduction response in knee osteoarthritis. As developed countries enter an aging era, interest in osteoarthritis treatments has increased. Kangstem Biotech's 'OSCA' is an innovative new drug cure, and with the Phase 1 MRI results announcement upcoming, market expectations for safety and efficacy are high.
Kangstem Biotech is preparing to announce the Phase 3 clinical trial results of the atopic dermatitis stem cell treatment 'Purestem-ADju' and the Phase 1 clinical trial results of the fundamental osteoarthritis treatment 'Purestem-OA Kitju,' which is administered via a single injection.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
